scispace - formally typeset
D

Derek L. Stirewalt

Researcher at Fred Hutchinson Cancer Research Center

Publications -  112
Citations -  17324

Derek L. Stirewalt is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 42, co-authored 101 publications receiving 15718 citations. Previous affiliations of Derek L. Stirewalt include University of Washington Medical Center & University of Washington.

Papers
More filters
Journal ArticleDOI

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

TL;DR: In this paper , the authors evaluated the annotated lncRNA landscape by transcript sequencing of 1,298 pediatric and 96 adult acute myeloid leukemia (AML) specimens and found that lncScores added to overall classification accuracy with at least comparable predictive performance to current stratification methods that rely on multiple assays.
Journal ArticleDOI

Requirement for N6-Methyladenosine mRNA Methylation during Human Erythropoiesis

TL;DR: In this article , the N6-methyladenosine (m6A) mRNA methyltransferase (MTase) complex was found to be required for human erythropoiesis in bone marrow-derived and G-CSF-mobilized CD34+ cells.
Patent

Methods and compositions for measuring radiation exposure in a subject

TL;DR: In this paper, a method for assessing exposure to ionizing radiation comprising the steps of (a) measuring the RNA expression level of certain biomarker genes in a biological sample; (b) correcting the RNA expressions of the measured biomarker in step (a), to a reference standard or threshold value, and (c) comparing the RNA expressed level of the biomarker measured in step(a) and corrected in accordance with step(b) to the corrected expression of a calibration sample or threshold values, wherein a difference in expression level between the biomarkers in the biological sample and the calibration
Journal ArticleDOI

Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition

TL;DR: In this paper , a focused drug screen using inhibitors targeting different DNA damage response pathways and drugs that inhibit DNA replication or DNA metabolic processes was performed to identify novel therapeutic targets in SF-mutant myeloid malignancies.